Antitumor agent-101

Antitumor agent-101 是一种赖氨酸甲基转移酶 G9a/GLP 的选择性共价抑制剂,对 G9a 和 GLP 的 IC50 分别为 8.5 nM 和 5.5 nM,并在 PANC-1 异种移植模型中显示出抗肿瘤效果。
产品编号: MS-Z25735 CAS No.: 2848632-52-8
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Antitumor agent-101 是一种赖氨酸甲基转移酶 G9a/GLP 的选择性共价抑制剂,对 G9a 和 GLP 的 IC50 分别为 8.5 nM 和 5.5 nM,并在 PANC-1 异种移植模型中显示出抗肿瘤效果。

生物实验数据

生物活性 Antitumor agent-101 is a selective covalent inhibitor of the lysine methyltransferases G9a/GLP with IC50 values of 8.5 nM and 5.5 nM for G9a and GLP, respectively, and exhibits antitumor efficacy in a PANC-1 xenograft model.
IC50 & Target G9a:8.5 nM, GLP:5.5 nM
体外研究
(In Vitro)

Antitumor agent-101 (Compound 27) ( 0-5 μM;48 小时) 抑制 PANC-1 和 MDA-MB-231 细胞的增殖和克隆形成。
Antitumor agent-101 ( 0-10 μM;0-96 小时) 以浓度和时间依赖性方式有效降低 PANC-1 和 MDA-MB-231 细胞中的 H3K9me2 水平。

Cell Proliferation Assay

Cell Line: PANC-1 and MDA-MB-231 cells
Concentration: 0, 1.25, 2.5, 5 μM
Incubation Time: 48 hours
Result: Ihibited proliferation of PANC-1 and MDA-MB-231 cells with IC50s of 2.68 and 2.88 μM, respectively.
Significantly suppressed the colony formation in MDA-MB-231 and PANC-1 cell lines at 2.5 μM.

Western Blot Analysis

Cell Line: PANC-1 and MDA-MB-231 cells
Concentration: 2.5, 5, 10 μM
Incubation Time: 4, 48, 72, or 96 hours
Result: Effectively reduced H3K9me2 in PANC-1 and MDA-MB-231 cells in a concentration- and time-dependent manner.
Still significantly inhibited the levels of H3K9me2 in the cells treated with compound 27 were still significantly inhibited within 24h after Antitumor agent-101 was washed out, and the levels of H3K9me2 were recovered after 48h.
体内研究
(In Vivo)

Antitumor agent-101 (Compound 27) (2 mg/kg,腹腔注射,每周五天) 通过抑制 G9a/GLP 的甲基转移酶活性来抑制 PANC-1 异种移植肿瘤的生长。
Antitumor agent-101 (2 mg/kg,腹腔注射) 显示 Cmax 为 316 ng/mL,平均停留时间 (MRT) 为 0.61 小时。

Animal Model: PANC-1 xenograft tumor models in male Balb/c nu/nu mice
Dosage: 2 mg/kg
Administration: Intraperitoneal injection (i.p.), 5 days a week (5 days on and 2 days off).
Result: Exhibited potent antitumor activity with a tumor growth inhibition (TGI) rate of 52.2% with no obvious toxicity.
Showed lower levels of H3K9me2 than the vehicle group.
Animal Model: Male ICR Mice (Pharmacokinetic assay)
Dosage: 2 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Pharmacokinetic parameters for antitumor agent-101 (Compound 27) in rats
Route Dose (mg/kg) Cmax (ng/mL) AUC0-t (h•ng/mL) AUC0-Ꝏ (h•ng/mL) MRT (h)
i.p. 2 316 208 214 0.61
分子量

482.62

Formula

C26H38N6O3

CAS 号

2848632-52-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
Data Sheet (533 KB) 产品使用指南 (1538 KB)
参考文献
  • . Feng Z, et.al. Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP. J Med Chem. 2023 Jun 22;66(12):8086-8102.  [Content Brief]

  • . Feng Z, et.al. Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP. J Med Chem. 2023 Jun 22;66(12):8086-8102.

Antitumor agent-101 相关分类

  • Cancer
  • 肿瘤靶向治疗 肿瘤代谢与转移
  • Epigenetics GPCR/G Protein
  • Histone Methyltransferase GLP Receptor
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2

Keywords:

Antitumor agent-1012848632-52-8Antitumor agent101Antitumor agent 101Histone MethyltransferaseGLP ReceptorProtein lysine methyltransferasesG9aGLPPANC-1 xenograft modeMDA-MB-231 cellsInhibitorinhibitorinhibit

您最近查看的产品:

  • Antitumor agent-101
  • PROTAC EZH2 Degrader-45
  • EPZ-4777
  • 5-Octyl-α-ketoglutarate
  • PRMT5/EGFR-IN-1
  • WIZ degrader 1
  • GSK-3β/G9a-IN-1
  • (Rac)-NSD2-PWWP1-IN-4
  • EZH2-IN-11
  • PROTAC EZH2 Degrader-24
  • ZL-28-6
  • PTD2
  • MMSET-IN-1
  • PRMT5-MTA-IN-4
  • MRK-990

化学信息

CAS No. 2848632-52-8

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础